| Id: | acc4940 |
| Group: | 1sens |
| Protein: | SMAD2 |
| Gene Symbol: | Smad2 |
| Protein Id: | Q62432 |
| Protein Name: | SMAD2_MOUSE |
| PTM: | phosphorylation |
| Site: | Ser467 |
| Site Sequence: | SPSVRCSSMS----------- |
| Disease Category: | Respiratory system diseases |
| Disease: | Pulmonary Fibrosis |
| Disease Subtype: | |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | fasudil |
| Drug Info: | Fasudil is a rho - kinase inhibitor. It is used to improve cerebrovascular spasm after subarachnoid hemorrhage and has potential applications in the treatment of other vascular - related diseases. |
| Effect: | modulate |
| Effect Info: | "Fasudil indirectly inhibits TGF-beta1-mediated Smad2/3 phosphorylation by suppressing the activity of the RhoA/ROCK pathway, thereby alleviating manifestations of pulmonary fibrosis (PF) and pulmonary hypertension (PH), including elevated right ventricular systolic pressure and pulmonary vascular remodeling. This suggests that the RhoA/ROCK–TGF-beta1–Smad2/3 axis is coupled in PF/PH, and inhibiting this pathway holds therapeutic potential." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 23928001 |
| Sentence Index: | 23928001_0 |
| Sentence: | Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation. |
Sequence & Structure:
MSSILPFTPPVVKRLLGWKKSAGGSGGAGGGEQNGQEEKWCEKAVKSLVKKLKKTGRLDELEKAITTQNCNTKCVTIPSTCSEIWGLSTANTVDQWDTTGLYSFSEQTRSLDGRLQVSHRKGLPHVIYCRLWRWPDLHSHHELKAIENCEYAFNLKKDEVCVNPYHYQRVETPVLPPVLVPRHTEILTELPPLDDYTHSIPENTNFPAGIEPQSNYIPETPPPGYISEDGETSDQQLNQSMDTGSPAELSPTTLSPVNHSLDLQPVTYSEPAFWCSIAYYELNQRVGETFHASQPSLTVDGFTDPSNSERFCLGLLSNVNRNATVEMTRRHIGRGVRLYYIGGEVFAECLSDSAIFVQSPNCNQRYGWHPATVCKIPPGCNLKIFNNQEFAALLAQSVNQGFEAVYQLTRMCTIRMSFVKGWGAEYRRQTVTSTPCWIELHLNGPLQWLDKVLTQMGSPSVRCSSMS
No data.
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| S | 245 | D | Obesity | Phosphorylation | 29700281 |
| - | - | D | Chronic kidney disease | Phosphorylation | 23264657 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
